Search
Meet Robert Hills, our August volunteer of the month
Can you tell us what you do for EHA and when you started?
I’m a relatively recent volunteer for EHA, as I only started working with them on their Clinical Research Training in Hematology (CRTH) program in 2016.
King Baudouin Foundation – Calls with a relevance to hematology
The King Baudouin Foundation is an actor for change and innovation, serving the public interest and increasing social cohesion. It endeavours to maximise its impact through capacity building among organisations and people who contribute to building a better society.
Read moreMeet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Meet Robin Foà, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I have been a member of EHA from its beginning and have participated in all EHA Congresses.
Proposal for an EU Regulation on Clinical Trials: A joint statement from non-commercial and commercial organisations
This statement outlines the areas of agreement within the health and research communities on where the Regulation will improve the research environment. Aspects of the Regulation that could be improved to further support clinical research are also highlighted.
Read moreEHA Bilateral Collaborative Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreMeet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Meet Helen Papadaki, our January volunteer of the month
Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…
Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- »